Clinical trial
Capecitabine For Nasopharyngeal Cancer
NCT00095901 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00095901 |
|---|---|
| Title | Capecitabine For Nasopharyngeal Cancer |
| Official title | A Phase II Study Of Capecitabine In Previously Treated, Recurrent And/Or Metastatic Nasopharyngeal Carcinoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine |
| Enrollment | 3 |
| Start date | Jun 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Nov 9, 2004 |
| Last update posted | Mar 29, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: